Literature DB >> 6409773

Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients.

K Kølendorf, J Bojsen, T Deckert.   

Abstract

Clinical factors which might influence the absorption of subcutaneously injected 125I-NPH insulin were studied in 101 diabetics. The disappearance curve was monoexponential after a delay period of 1.5 +/- 0.8 h (mean +/- SD). Lipohypertrophy significantly prolonged insulin absorption (half life (T1/2) = 11.2 +/- 3.1 h, p = 0.0001). Low bicarbonate levels increased the absorption (T1/2 3.9 +/- 2.3 h, p less than 0.05). Lean diabetics had a faster absorption (6.2 +/- 1.9 h) than normal weight diabetics (7.5 +/- 2.0 h, p less than 0.02). Sex, age, diabetes duration and injection depth did not influence T1/2. The half life was significantly inversely correlated to the resting subcutaneous blood flow (r = 0.882, p less than 0.01). The overall interindividual coefficient of variation for insulin absorption in nonketotic diabetics was 27.4%. Also considerable intra-patient day-to-day variation was found (24.5%), and between different injection sites (30.2%). These variations emphasize the drawbacks of conventional insulin therapy in the management of insulin-requiring diabetics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409773     DOI: 10.1055/s-2007-1018694

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  11 in total

1.  The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection.

Authors:  A Hübinger; W Weber; W Jung; K Wehmeyer; F A Gries
Journal:  Clin Investig       Date:  1992-07

2.  Modeling absorption kinetics of subcutaneous injected soluble insulin.

Authors:  E Mosekilde; K S Jensen; C Binder; S Pramming; B Thorsteinsson
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

Review 3.  Can technological solutions for diabetes replace islet cell function?

Authors:  Justin M Gregory; Daniel J Moore
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

4.  Lipohypertrophy and the artificial pancreas: is this an issue?

Authors:  Lutz Heinemann; Larry Hirsch; Roman Hovorka
Journal:  J Diabetes Sci Technol       Date:  2014-06-16

Review 5.  The surgical patient with diabetes mellitus: guidelines for management.

Authors:  R L Schiff; M A Emanuele
Journal:  J Gen Intern Med       Date:  1995-03       Impact factor: 5.128

Review 6.  Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy?

Authors:  Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

Review 7.  Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Authors:  A Lindholm; L V Jacobsen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Pharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood.

Authors:  Dayu Lv; Sandip D Kulkarni; Alice Chan; Stephen Keith; Ron Pettis; Boris P Kovatchev; Leon S Farhi; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-03-09

9.  Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

Authors:  K Hermansen; P Fontaine; K K Kukolja; V Peterkova; G Leth; M A Gall
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

10.  Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring.

Authors:  Shinya Abe; Gaku Inoue; Satoru Yamada; Junichiro Irie; Hiroyuki Nojima; Kaoru Tsuyusaki; Kensuke Usui; Koichiro Atsuda; Toshikazu Yamanouchi
Journal:  Diabetes Metab Syndr Obes       Date:  2011-07-13       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.